IceCure System Successfully Treated Kidney Cancer Tumor

 

• Independent study concluded:
  - IceCure system offers significant advantage in ability to re-treat tumors that are initially resistant, achieving a subsequent local control rate of 100%
  - 92.4% of patients (N= 24) were discharged the day after cyroablation
  - The technology's ability to preserve renal function post-treatment is paramount for patients' quality of life
  - Findings serve as a guide for medical professionals in choosing efficient, cost-effective, and patient-friendly treatment options, thereby benefiting society at large by optimizing kidney tumor management
• Success across multiple indications supports ProSense®'s commercialization, particularly in facilities that can use one device across multiple specialties

https://www.biospace.com/article/releases/icecure-system-successfully-treated-kidney-cancer-tumor-with-92-percent-disease-free-survival-rate-and-100-percent-secondary-local-control-rate/